유한양행, 길리어드 API 수주 1년 새 4700억 누적…고환율 수혜

This development highlights a critical shift in the global pharmaceutical supply chain as multinational companies reduce their dependence on China and turn to reliable CDMO partners like Yuhan. It demonstrates how geopolitical tensions, combined with a strong dollar, can significantly accelerate the financial growth and strategic importance of alternative API manufacturers. Industry stakeholders should closely monitor this trend, as it signals a long-term structural realignment in global drug production.